Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

The expression of glial fibrillary acidic protein in the brain of streptozotocin rat model of sporadic Alzheimer’s disease (CROSBI ID 605027)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Knezović, Ana ; Knapić, Marina ; Šimić, Goran ; Šalković-Petrišić, Melita The expression of glial fibrillary acidic protein in the brain of streptozotocin rat model of sporadic Alzheimer’s disease // Clinical Neuropathology 31(4) / Ironside, James (ur.). Edinburgh: British Neuropathological Society, 2012. str. 290-290

Podaci o odgovornosti

Knezović, Ana ; Knapić, Marina ; Šimić, Goran ; Šalković-Petrišić, Melita

engleski

The expression of glial fibrillary acidic protein in the brain of streptozotocin rat model of sporadic Alzheimer’s disease

Introduction: Central administration of streptozotocin (STZ-icv) induces Alzheimer-like behavioural and neurochemical changes in rat due to the STZ-icv rat has been recently proposed as its animal model. Activated microglia and astrocytes were found in the cortex and hippocampus up to 8 weeks after the STZ-icv administration. We have investigated the STZ-icv dose-dependency of astrogliosis development 1 week and 3 months after the STZ-icv treatment. Methods: Adult male Wistar rats were administered STZ (0.1, 1 and 3 mg/kg dose) or vehicle (controls) icv injections and sacrificed 1 week and 3 months afterwards. Paraffin-embedded brain sections of pre-mortally fixative perfused animals were analysed by immunohistochemistry of glial fibrillary acidic protein (GFAP), a marker of astrogliosis. Results: Highly increased GFAP expression both in number and cell size was found focused in the cortex, around the cannula penetration area, and in hippocampus 1 week after the STZ-icv administration with all STZ-icv doses as well in the control animals. Three months after the treatment, distribution and cell size were found normalized in all treated groups as well as their number, with the exception of slightly increase with the 0.3 mg/kg STZ-icv dose only. Conclusions: Preliminary results demonstrate that STZ-icv rat model develops acute, non-specific anti-inflammatory response, regardless the STZ-icv dose, which tends to normalize three months after the treatment. Acknowledgement: Supported by the Unity Through Knowledge Fund (UKF 64-10) and MZOS.

astrocyte; streptozotocin; Alzheimer's disease

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

290-290.

2012.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Clinical Neuropathology 31(4)

Ironside, James

Edinburgh: British Neuropathological Society

Podaci o skupu

10th European Congress of Neuropathology

poster

06.06.2012-09.06.2012

Edinburgh, Ujedinjeno Kraljevstvo

Povezanost rada

Temeljne medicinske znanosti